KRYS vs. CRSP, IMVT, HALO, SWTX, IBRX, IOVA, IMCR, CGON, ACLX, and RVMD
Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include CRISPR Therapeutics (CRSP), Immunovant (IMVT), Halozyme Therapeutics (HALO), SpringWorks Therapeutics (SWTX), ImmunityBio (IBRX), Iovance Biotherapeutics (IOVA), Immunocore (IMCR), CG Oncology (CGON), Arcellx (ACLX), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics (NASDAQ:CRSP) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk, community ranking and dividends.
Krystal Biotech has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
CRISPR Therapeutics presently has a consensus target price of $75.43, indicating a potential upside of 44.64%. Krystal Biotech has a consensus target price of $171.00, indicating a potential upside of 7.26%. Given Krystal Biotech's higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Krystal Biotech.
In the previous week, Krystal Biotech had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 30 mentions for Krystal Biotech and 24 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.36 beat Krystal Biotech's score of 0.11 indicating that Krystal Biotech is being referred to more favorably in the news media.
Krystal Biotech's return on equity of -8.09% beat CRISPR Therapeutics' return on equity.
69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 14.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
CRISPR Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
CRISPR Therapeutics received 179 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 66.83% of users gave Krystal Biotech an outperform vote while only 65.38% of users gave CRISPR Therapeutics an outperform vote.
Summary
Krystal Biotech beats CRISPR Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Krystal Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Krystal Biotech Competitors List
Related Companies and Tools
